Home
NewsNewsNexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
Nexpring Health, a global leader in assisted reproductive technology (ART) solutions, has announced a strategic investment in May Health, a medical device company. This partnership aims to advance a pioneering treatment for PCOS-Related Infertility, addressing a significant gap in women's health. Nexpring Health joined a €10 million ($11.7M) financing round alongside other key investors, including Sofinnova Partners, Trill Impact, and Bpifrance.
Polycystic ovary syndrome (PCOS) is a widespread endocrine condition affecting approximately 10–13% of reproductive-aged women worldwide. It stands as a primary cause of female infertility, as the condition often prevents consistent ovulation. For many patients, the struggle to conceive is a defining challenge, leading to a critical need for innovative solutions to manage PCOS-Related Infertility.
May Health’s breakthrough technology, the Anavi™ System, offers a novel approach to this issue. It is designed as a one-time, office-based procedure intended to restore ovulation in women who have not responded to or are unable to use traditional first-line therapies. The system has already reached significant milestones, receiving CE Mark certification in October 2025. Currently, May Health is advancing its pivotal U.S. Investigational Device Exemption (IDE) trial, known as the REBALANCE study, as it seeks FDA marketing authorisation. The REBALANCE trial is a multicentre, randomised controlled study currently enrolling participants at over 15 fertility centres across the United States.
Wil Boren, CEO of Nexpring Health, emphasised that the investment reflects the company’s commitment to redefining fertility care and supporting innovations that change patient outcomes. Boren stated that May Health’s work helps move the entire field forward by expanding clinical options for both professionals and patients. Colby Holtshouse, President and CEO of May Health, added that women have long required more options to support their family-building journeys while managing PCOS-Related Infertility.
Through this collaboration, Nexpring Health continues its mission of placing clinicians and embryologists at the centre of every breakthrough. By backing the Anavi™ System, the company aims to provide reproductive medicine professionals with the tools needed to deliver consistent, confident outcomes for those hoping to start a family
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
